PCSK9 inhibition across a wide spectrum of patients: for whom is it efficacious?

26 August 2017 (15:50 - 16:05)

Organised by:

About the speaker

Doctor G Kees Hovingh

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

4 More presentations in this session

Presentation thumbnail

Introduction - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.

Doctor M. Farnier (Dijon, FR)

Presentation thumbnail

Understanding new PCSK9 outcome data: from the LDL-C hypothesis to LDL-c causality.

Professor J. Chapman (Paris, FR)

Presentation thumbnail

PCSK9 inhibition & CV events: review of recent and upcoming hard endpoint outcome trials.

Professor P. Sever (London, GB)

Presentation thumbnail

Discussion - PCSK9 inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies.

Professor W. Koenig (Munich, DE) Doctor M. Farnier (Dijon, FR)

Access the full session

Session thumbnail

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition & cardiovascular outcomes: review of lipid targets and treatment strategies (EBAC Accredited)

The Event

ESC Congress 2017

26 August 2017 15:50 CET

You may be interested in

Congress Presentation

Novel insights into the management of German patients with very high cardiovascular risk eligible for PCSK9 inhibitor treatment: baseline characteristics from the PERI-DYS study

27 August 2021

Webinar

Percutaneous interventions in patients with coronary artery disease and specific clinical conditions - IC Core Curriculum 6

9 November 2022

Webinar

How to treat patients with borderline dyslipidemia

8 February 2023

Congress Presentation

What is the benefit of starting earlier?

30 August 2024

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources

novo-nordisk

Explore sponsored resources